UK generics industry: "Let's shut the stable door before the horse bolts"
This article was originally published in SRA
The British Generic Manufacturers Association says it is working with the government to address long term issues affecting generics companies before they start to affect the sustainability of the industry1. Increasing pricing pressures, intellectual property rights issues and current levels of competition could all conspire to threaten the industry if action is not taken immediately, said the association at its annual general meeting.
You may also be interested in...
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.